Any nobel prize (though medicine is most likely) primarily for the development of or work done on GLP-1 drugs or any specific drugs in this category, including semaglutide, tirzepatide, etc
1,000Two signals this cycle. Clarivate's 2026 Citation Laureates in Physiology or Medicine, announced 17 September, are led by the GLP-1 trio: Daniel Drucker (Toronto), Jens Juul Holst (Copenhagen) and Svetlana Mojsov (Rockefeller), and the 2024 Lasker~DeBakey Clinical Award already went to GLP-1 (Habener, Knudsen, Mojsov). Medicine is announced on Monday 5 October. One thing to keep separate from the obesity story if it comes up in a citation: GLP-1 drugs are now also being tested as aging drugs, with semaglutide one of the three arms of VITAL-H (726 adults aged 60 to 65, ARPA-H funded), and SELECT showed a 19% lower all-cause death rate in overweight adults with heart disease. Whether any drug gets an aging indication is a separate race, and the only regulator acceptance of lifespan extension as an indication so far is for dog drugs (mine): /w0lph/which-species-will-get-the-first-re